{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.15","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"7.9","upperLimit":"NA","value":"20.0"},{"comment":"NA - The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG001","lowerLimit":"3.4","upperLimit":"NA","value":"15.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Overall survival will be summarized as time from first protocol treatment until death from any cause, using the product-limit Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 50, 75 or 100 mg/day of TRC102 PO QD on days 1-4, 500 mg/m\\^2 of pemetrexed disodium IV over 10 minutes, and 60 or 75 mg/m\\^2 of cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue TRC102 and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.","id":"OG000","title":"Arm A (TRC102, Pemetrexed Disodium, Cisplatin) - Phase I"},{"description":"Patients receive 50 mg/day of TRC102 PO QD on days 1-4 and 500 mg/m\\^2 of pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue TRC102 and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.","id":"OG001","title":"Arm B (TRC102, Pemetrexed Disodium) - Phase II"}],"paramType":"MEDIAN","populationDescription":"Pre-specified in the Study Protocol to collect, analyze, and report data for this Outcome Measure by Phase and not by dose-level.","reportingStatus":"POSTED","timeFrame":"From start of treatment to time of death from any cause, assessed up to at least 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}